That said, Recursion doesn't have a single therapy on the market yet. Over the past four years, the company has made little ...

Biotech Recursion announced a definitive merger agreement with drug design and development company Exscientia on Thursday morning. The combined company, which is expected to yield annual synergies of ...

Recursion's AI-Powered Drug Revolution Recursion is a clinical-stage TechBio company that is fundamentally built upon the principles of artificial intelligence and machine learning.

Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said they will merge into one company.

Recursion Pharmaceuticals is still just a clinical-stage company. None of its products are in phase 3 trials, although it expects more than half a dozen data readouts over the next 18 months.

Recursion Pharmaceuticals (RXRX) reachead $5.41 at the closing of the latest trading day, reflecting a -1.64% change compared to its last close.

Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special ...

Recursion Pharmaceuticals is still just a clinical-stage company. None of its products are in phase 3 trials, although it expects more than half a dozen data readouts over the next 18 months.

Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.

Recursion Pharmaceuticals recently reported positive phase 2 results for REC-994, a potential treatment for symptomatic cerebral cavernous malformation, a disease caused by the abnormal formation ...